News
-
-
PRESS RELEASE
Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product
Jaguar Health, Inc. announces commercial launch at ASCO Annual Meeting for Gelclair, FDA-approved oral mucositis product. Focus on cancer supportive care with phase 3 OnTarget trial results impending -
-
-
-
-
-
PRESS RELEASE
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
Jaguar Health, Inc. to conduct investor webcast on May 14, 2024 at 8:30 a.m. Eastern to review first-quarter 2024 financials and provide corporate updates. Company plans to file its Earnings Report on the same day -
-
PRESS RELEASE
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe
Jaguar Health's crofelemer granted Orphan Drug Designation by FDA and EMA for MVID and SBS. Clinical trials submitted in Italy and Germany for SBS and MVID treatment. Jaguar focuses on plant-based medicines for gastrointestinal distress
